Impact of ERCC1 gene polymorphisms on response to cisplatin based therapy in oral squamous cell carcinoma (OSCC) patients

• Autors principals: M L Avinash Tejasvi (Autor), G Maragathavalli (Autor), Uday Kumar Putcha (Autor), M Ramakrishna (Autor), R Vijayaraghavan (Autor), C K Anulekha Avinash (Autor)
• Format: Llibre
• Publicat: Wolters Kluwer Medknow Publications, 2020-01-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Background and Objectives: Cisplatin is one of the major drugs that used in the treatment of oral cancer.Excision repair cross-complementation group 1 (ERCC1) is a key DNA repair gene in the nucleotide excision repair pathway which is activated in the repair of intra- and interstrand DNA crosslink c...